Search This Blog

Wednesday, April 1, 2026

Artemis II countdown continues: working to resolve communication with the flight termination system

 5 p.m.

Although the countdown to today’s Artemis II launch is continuing to progress, the Eastern Range has identified an issue that they are currently working to resolve related to their communication with the flight termination system. The flight termination system is a safety system that allows engineers on the ground to send a signal to destruct the rocket if it were to veer off course during ascent, to protect public safety. Without assurance that this system would work if needed, today’s launch would be no-go. However, engineers have devised a way to verify the system and are currently preparing to test this solution.

https://www.nasa.gov/blogs/missions/2026/04/01/live-artemis-ii-launch-day-updates/

Nuvation Bio now has global development and commercialization rights for safusidenib



With acquisition of Japan rights, Nuvation Bio now has global development and commercialization rights for safusidenib

Agreement provides Nuvation Bio ownership of global clinical development program, inclusive of clinical trials, past and current data generation, and future publications

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the company has amended its existing exclusive license agreement for safusidenib with Daiichi Sankyo (TSE :4568) to include Japan rights, effectively securing exclusive global development and commercialization rights of the investigational medicine. The agreement, as amended, enables Nuvation Bio to expand its ongoing pivotal SIGMA study of safusidenib into Japan, and provides rights to all previously generated and future data to support further publication of safusidenib results in IDH1-mutant glioma.

Safusidenib is a novel, oral, potent, brain-penetrant, selective inhibitor of mutant IDH1 that is currently being evaluated in the ongoing Phase 3 SIGMA study for the maintenance treatment of patients with IDH1-mutant astrocytoma who have high-risk features following standard-of-care.

Raymond James Upgrades UNH to Outperform, Sets Price Target at $330

 On April 1, 2026, Raymond James analyst John Ransom upgraded UnitedHealth Group (UNH) from a "Market Perform" to an "Outperform" rating. The analyst also announced a new price target of $330 USD for the stock. This marks a significant change in sentiment towards UNH by Raymond James.

Historically, UnitedHealth Group UNH has seen various analyst actions over the past few months:

  • On February 5, 2026, Mizuho's Ann Hynes maintained an "Outperform" rating but lowered the price target from $430 to $350 USD.
  • On February 2, 2026, JP Morgan's Lisa Gill maintained an "Overweight" rating, lowering the price target from $425 to $389 USD.
  • Also on February 2, 2026, Truist Securities' David Macdonald maintained a "Buy" rating and decreased the price target from $410 to $370 USD.
  • On January 30, 2026, Wells Fargo's Stephen Baxter maintained an "Overweight" rating while dropping the price target from $400 to $370 USD.
  • On January 30, 2026, Barclays' Andrew Mok maintained an "Overweight" rating, adjusting the price target down from $391 to $327 USD.

'Iran says Hormuz future to be decided with Oman after war'

 Iran’s Foreign Minister Abbas Araghchi said the future of the Strait of Hormuz would be decided jointly by Iran and Oman after the war, according to an exclusive interview with Al Jazeera broadcast on Wednesday.

Araghchi stated that the waterway lies within the territorial and internal waters of Iran and Oman, and that any post-war arrangements regarding transit and governance would be determined solely by the two coastal states.

“The reality is that it lies within the internal waters of Iran and Oman,” he said. “What arrangements will be considered after the war is a matter related to Iran and Oman.”

The Strait of Hormuz is one of the world’s most critical shipping chokepoints, through which roughly 20 per cent of global seaborne traded oil and significant volumes of liquefied natural gas pass from Gulf producers to international markets.

These remarks come one month into the current war between Iran, Israel, and the United States, which began with surprise Israeli and US airstrikes on Iranian targets on February 28. Since the outbreak of hostilities, Iran has exerted greater control over the Strait of Hormuz as a wartime measure.

Araghchi said the strait remains open, but access is restricted for countries involved in the conflict with Iran.

“From our point of view, the Strait is currently open and is closed only to those who are at war with Iran,” he said.

He added that vessels from other countries have continued to pass through, with many engaging directly with Iran to arrange safe transit.

“Some of them have entered into negotiations with us… and for many of them, especially those from friendly countries, we have put arrangements in place so they can pass through the Strait safely,” he said.

As part of these arrangements, Iran has been imposing significant fees, reportedly up to $2 million per tanker in some cases, for safe passage. These payments are often coordinated directly with Iranian authorities, sometimes in non-USD currencies such as Chinese yuan.

China, one of the largest buyers of Iranian and Gulf oil, has had mixed experiences. Several Chinese and Hong Kong-flagged tankers initially turned back in late March after warnings from Iran’s Islamic Revolutionary Guard Corps (IRGC). Others later secured passage after direct negotiations and arrangements with Iranian authorities.

Araghchi emphasised that ensuring navigation safety, environmental protection, and traffic management in the strait should be handled by the coastal states.

“Ensuring the safety of ship passage, addressing environmental issues, navigation, traffic and regulations all require order and arrangements that pertain to the coastal states of this strait, Iran and Oman,” he said.

He also described the strait’s potential future role as a “waterway of peace” once the conflict ends.

The partial restrictions and disruptions in the Strait of Hormuz have caused significant volatility in global energy markets. Oil prices spiked sharply after the late February strikes, with Brent crude pushing toward and above $100 per barrel at peaks. Daily tanker traffic has dropped dramatically, leading to higher global energy costs, increased gasoline prices in many countries, and the release of strategic reserves by consuming nations to ease supply pressures.

Araghchi made the remarks as part of a wider interview discussing regional security and Iran’s position in the ongoing conflict.

https://www.arabianbusiness.com/politics/iran-says-hormuz-future-to-be-decided-with-oman-after-war

Merit Medical acquires imaging oncology company View Point Medical for $140M

 Merit Medical Systems (Nasdaq:MMSI) announced today that it acquired View Point Medical in a deal worth approximately $140 million.

South Jordan, Utah-based Merit agreed to pay $90 million in cash at closing. The deal also features two deferred payments of $25 million set for no later than the first and second anniversaries of the closing date, respectively. Through the merger transaction, Carlsbad, California-based View Point is now a wholly-owned subsidiary of Merit.

View Point manufactures the OneMark detection imaging system and OneMark tissue markers. The FDA-cleared OneMark system features a surgical detection console and ultrasound-enhanced tissue markers. OneMark breast markers use silica microspheres, which don’t emit energy but change the timing of waves from ultrasound energy, which creates a bright color image showing the location of the marker.

After placement, View Point designed its tissue markers for visibility across commonly used imaging modalities. They also minimize interference with imaging studies.

Combining the Merit Scout surgical guidance platform with OneMark provides more localization options during the initial diagnostic biopsy. This could reduce the need for a second procedure to mark the location of a tumor prior to surgery.

Merit expects its acquisition to contribute revenue between $2 million and $4 million from today through the end of 2026. It anticipates an approximately 5¢ dilution to adjusted EPS, diluting both full-year GAAP net income and GAAP EPS.

For the 12 months ending Dec. 31, 2027, the company expects revenues between $14 million and $16 million. It anticipates at least 20% growth in OneMark sales per year.

https://www.massdevice.com/merit-medical-acquires-imaging-oncology-company-view-point-medical-for-140m/

Pfizer, BioNTech halt US COVID vaccine study after trial recruitment struggle



Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to generate the needed data.

In a letter to trial investigators dated March ‌30, seen by Reuters and previously unreported, Pfizer said it would stop surveillance for signs of COVID illness of all participants in the study after April ‌3.



Enrollment was closed on March 6, following a review of current epidemiological trends, it said.


The move comes as COVID vaccine makers grapple with pushback from the U.S. administration and weak U.S. demand for the shots.

The U.S. Food ​and Drug Administration toughened requirements for COVID vaccine use last year, including asking for large, placebo-controlled trials in the 50-64 age group for it to be included in recommendations.

Pfizer and BioNTech told Reuters they had informed the FDA about their intent to halt the COVID-19 vaccine study, citing challenges getting enough participants. The target enrollment was roughly 25,000 to 30,000 participants.



"This study is not ending as a result of any safety or benefit-risk concerns. We intend to stop the study due to slow enrollment and therefore the inability to generate relevant post-marketing data," the ‌companies said.

Shares of Pfizer and U.S.-listed shares of BioNTech were ⁠up about half a percent, while rival COVID-vaccine maker Moderna was up 2%.

FDA vaccine chief Vinay Prasad, who had pushed for the placebo-controlled trials in healthy adults and children, is leaving the agency this month. At the meeting of the FDA's vaccine advisers last year, some ⁠experts warned that requiring large new trials could delay or limit the availability of updated shots for lower-risk groups.

The FDA was not immediately available for comment.

Bayer in Talks With European Governments on Higher Drug Prices

 


Bayer AG is in discussions with governments in Europe, Japan and other wealthy countries to push for higher prices on new medicines as the US seeks to rein in drug costs.

“In Europe, we need to raise the price level for new product launches,” said Stefan Oelrich, the head of Bayer’s pharmaceuticals division, in an interview. “Otherwise, as an industry — and this naturally applies to us as well — we’ll be faced with additional discounts in the US that wouldn’t allow us to recoup our total expenses.”

https://www.bloomberg.com/news/articles/2026-04-01/bayer-in-talks-with-european-governments-on-higher-drug-prices